Abstract 73P
Background
Although immunotherapy (IO) offers significant advances in the clinical management of NonSmall Cell Lung Cancer (NSCLC), durable benefits are not achieved in all patients. Mechanisms of resistance to IO in NSCLC are complex, mainly comprising tumor and infiltrating immune cells. However, resistance landscape against PD-1 blockade remains unclear. More recently, some evidence has provided evidence for metformin overcoming primary resistance to PD-1 inhibitor in mutant NSCLC models. Considering this, we aimed to assess the impact of the combined treatment of metformin plus atezolizumab on antitumor immune response from NSCLC patients-derived peripheral blood immune cells (PBMCs).
Methods
mRNA and protein expression of cGAS-STING downstream pathway and monocyte M1 marker levels were measured in PBMCs from NSCLC patients. MTS assay was used to assess cell viability of NSCLC cell lines co-cultured with PBMCs or monocyte-conditioned medium. Evaluation of senescence phenotype was also performed based on a histochemical stain for the detection of β-galactosidase activity. Colony-forming ability of NSCLC cell lines co-cultured with immune cells derived from NSCLC patients (pre-treated with metformin 2 mM + atezolizumab 10 μg/ml for 48h) was also assessed.
Results
Metformin ± atezolizumab was able to activate the cGAS-STING pathway in PBMC-derived lymphocytes from NSCLC patients and reduce in vitro cell viability of NSCLC cells in 2D co-culture. Colony formation ability of NSCLC cell lines was reduced by activated lymphocytes pre-treated with metformin ± atezolizumab. Evaluation of the senescent phenotype in PBMC-isolated monocytes showed the greatest reduction in blue staining in the presence of the combined treatments. We also observed a reduction in cell viability by MTS assay of NSCLC cells cultured with monocyte-conditioned media treated with metformin ± atezolizumab. Furthermore, we found increased levels of M1 markers (TNFα, IL1β) in monocytes treated with the combined therapy.
Conclusions
Our results provide a novel role for synergistic effects of metformin combined with IO in enhancing the anti-tumor activity of multiple immune cells subsets from NSCLC patients.
Editorial acknowledgement
NA
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract